| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD) |
NCT00127153: A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013) |
|
|
| Completed | 3 | 130 | Japan | V110, pneumococcal vaccine polyvalent | Merck Sharp & Dohme LLC | Healthy, Pneumococcal Infections | 05/05 | 05/05 | | |
NCT00496093: Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011) |
|
|
| Completed | 3 | 133 | NA | Pneumococcal Vaccine, Polyvalent (23-valent), V110, PNEUMOVAX™ 23 | Merck Sharp & Dohme LLC | Pneumococcal Infection | 01/06 | 01/06 | | |
| Completed | 3 | 120 | Europe | Pneumococcal vaccine | GlaxoSmithKline | Infections, Streptococcal | | 12/06 | | |
NCT00535730: ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) |
|
|
| Completed | 3 | 473 | NA | Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™, ZOSTAVAX™, Comparator: placebo (concomitant-vaccine matched), Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23, PNEUMOVAX™ 23 | Merck Sharp & Dohme LLC | Herpes Zoster, Pneumococcal Infection | 02/08 | 02/08 | | |
NCT00560950: Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) |
|
|
| Completed | 3 | 143 | NA | pneumococcal 23v polysaccharide vaccine, V110, PNEUMOVAX | Merck Sharp & Dohme LLC | Pneumococcal Infection | 05/08 | 05/08 | | |
| Completed | 3 | 227 | RoW | 23vPPV, dTpa (Pneumovax, Boostrix), Pneumovax, Boostrix | Menzies School of Health Research, National Health and Medical Research Council, Australia | Middle Ear Effusion, Tympanic Membrane Perforation, Acute Otitis Media, Pneumococcal Infections | 02/11 | 07/11 | | |
NCT01432158: Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines |
|
|
| Completed | 3 | 4 | Europe | Prevenar 13, Pneumovax II | University of Oxford, Mason Medical Research Trust | Pneumococcal Disease | 08/12 | | | |
NCT02285036: Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children |
|
|
| Completed | 3 | 1660 | RoW | vaccination PPV23, vaccination PNEUMOVAX 23 | Walvax Biotechnology Co., Ltd., Guangxi Center for Disease Control and Prevention, Air Force Military Medical University, China | Pneumococcal Infectious Diseases | 12/12 | 05/13 | | |
NCT01734239 / 2015-001656-29: A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018) |
|
|
| Completed | 3 | 102 | NA | Pneumovax™ 23, V110 | Merck Sharp & Dohme LLC | Pneumococcal Disease | 10/13 | 10/13 | | |
NCT02079207: Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine |
|
|
| Completed | 3 | 767 | RoW | NBP606, Prodiax-23 | SK Chemicals Co., Ltd. | Pneumococcal Infections | 10/14 | 03/15 | | |
